Antipsychotic drug effects on brain morphology in first-episode psychosis.

BACKGROUND Pathomorphologic brain changes occurring as early as first-episode schizophrenia have been extensively described. Longitudinal studies have demonstrated that these changes may be progressive and associated with clinical outcome. This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia. OBJECTIVE To test a priori hypotheses that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treated patients and that gray matter and lateral ventricle volume changes are associated with changes in psychopathology and neurocognition. DESIGN Longitudinal, randomized, controlled, multisite, double-blind study. Patients treated and followed up for up to 104 weeks. Neurocognitive and magnetic resonance imaging (MRI) assessments performed at weeks 0 (baseline), 12, 24, 52, and 104. Mixed-models analyses with time-dependent covariates evaluated treatment effects on MRI end points and explored relationships between MRI, psychopathologic, and neurocognitive outcomes. SETTING Fourteen academic medical centers (United States, 11; Canada, 1; Netherlands, 1; England, 1). PARTICIPANTS Patients with first-episode psychosis (DSM-IV) and healthy volunteers. INTERVENTIONS Random allocation to a conventional antipsychotic, haloperidol (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d). MAIN OUTCOME MEASURES Brain volume changes assessed by MRI. RESULTS Of 263 randomized patients, 161 had baseline and at least 1 postbaseline MRI evaluation. Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not. A matched sample of healthy volunteers (n = 58) examined contemporaneously showed no change in gray matter volume. CONCLUSIONS Patients with first-episode psychosis exhibited a significant between-treatment difference in MRI volume changes. Haloperidol was associated with significant reductions in gray matter volume, whereas olanzapine was not. Post hoc analyses suggested that treatment effects on brain volume and psychopathology of schizophrenia may be associated. The differential treatment effects on brain morphology could be due to haloperidol-associated toxicity or greater therapeutic effects of olanzapine.

[1]  A. Janowsky,et al.  Effect of haloperidol and clozapine on the density of “perforated” synapses in caudate, nucleus accumbens, and medial prefrontal cortex , 2005, Psychopharmacology.

[2]  A. Deutch,et al.  Effects of Antipsychotic Drugs on Neurogenesis in the Forebrain of the Adult Rat , 2004, Neuropsychopharmacology.

[3]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[4]  D. Weinberger,et al.  Effects of Chronic Haloperidol and Clozapine Treatment on Neurogenesis in the Adult Rat Hippocampus , 2004, Neuropsychopharmacology.

[5]  Philippe Mailly,et al.  34th Annual Meeting of Society for Neuroscience , 2004 .

[6]  H. Holcomb,et al.  Clozapine but not Haloperidol Re-establishes Normal Task-Activated rCBF Patterns in Schizophrenia within the Anterior Cingulate Cortex , 2004, Neuropsychopharmacology.

[7]  J. Lieberman,et al.  Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. , 2003, The American journal of psychiatry.

[8]  F. Fumagalli,et al.  Effect of antipsychotic drugs on brain‐derived neurotrophic factor expression under reduced N‐methyl‐D‐aspartate receptor activity , 2003, Journal of neuroscience research.

[9]  Vincent Magnotta,et al.  Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. , 2003, Archives of general psychiatry.

[10]  Deanna Greenstein,et al.  Structural brain MRI abnormalities in healthy siblings of patients with childhood-onset schizophrenia. , 2003, The American journal of psychiatry.

[11]  M. Desco,et al.  Cerebral metabolism and risperidone treatment in schizophrenia , 2003, Schizophrenia Research.

[12]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[13]  D. Keegan,et al.  Expression of brain‐derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs , 2003, Journal of neuroscience research.

[14]  J. Lieberman,et al.  Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents , 2003, Neuropsychopharmacology.

[15]  R. Kahn,et al.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. , 2002, Archives of general psychiatry.

[16]  J. Waller,et al.  Atypical neuroleptics stimulate neurogenesis in adult rat brain , 2002, Journal of neuroscience research.

[17]  Guido Gerig,et al.  Multisite validation of image analysis methods: assessing intra- and intersite variability , 2002, SPIE Medical Imaging.

[18]  M. First,et al.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .

[19]  S. Heckers,et al.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia , 2001, Biological Psychiatry.

[20]  Patricia Desmond,et al.  A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia , 2001, Schizophrenia Research.

[21]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[22]  J. Lieberman,et al.  Longitudinal study of brain morphology in first episode schizophrenia , 2001, Biological Psychiatry.

[23]  K O Lim,et al.  Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. , 2001, Archives of general psychiatry.

[24]  P. Greengard,et al.  Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex , 2001, Biological Psychiatry.

[25]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[26]  G. Duncan,et al.  Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.

[27]  T. Nordahl,et al.  The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia: Evidence of a Sex Effect , 1999, Neuropsychopharmacology.

[28]  Koenraad Van Leemput,et al.  Automated model-based tissue classification of MR images of the brain , 1999, IEEE Transactions on Medical Imaging.

[29]  Jeffrey A Lieberman,et al.  Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective , 1999, Biological Psychiatry.

[30]  N C Andreasen,et al.  Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. , 1999, The American journal of psychiatry.

[31]  P. Goldman-Rakic,et al.  Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure , 1999, Biological Psychiatry.

[32]  J. Rapoport,et al.  Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. , 1999, Archives of general psychiatry.

[33]  R. McCarley,et al.  MRI anatomy of schizophrenia , 1999, Biological Psychiatry.

[34]  Paul J. Harrison.  The neuropathology of schizophrenia , 2008 .

[35]  P. Goldman-Rakic,et al.  The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.

[36]  B. Woods.  Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. , 1998, The American journal of psychiatry.

[37]  J. Lieberman,et al.  Striatal enlargement in rats chronically treated with neuroleptic , 1998, Biological Psychiatry.

[38]  F. Holsboer,et al.  Induction of NF-κB Activity during Haloperidol-Induced Oxidative Toxicity in Clonal Hippocampal Cells: Suppression of NF-κB and Neuroprotection by Antioxidants , 1998, The Journal of Neuroscience.

[39]  Lina Shihabuddin,et al.  Ventricular Enlargement in Poor-Outcome Schizophrenia , 1998, Biological Psychiatry.

[40]  J. Bloomquist,et al.  Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia , 1998, Brain Research.

[41]  S. Lawrie,et al.  Brain abnormality in schizophrenia , 1998, British Journal of Psychiatry.

[42]  Tyrone D. Cannon,et al.  A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. , 1998, Archives of general psychiatry.

[43]  N. Andreasen,et al.  Effect of Antipsychotics on Regional Cerebral Blood Flow Measured with Positron Emission Tomography , 1997, Neuropsychopharmacology.

[44]  L. DeLisi,et al.  Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia , 1997, Psychiatry Research: Neuroimaging.

[45]  J. Coyle,et al.  Tardive dyskinesia and substrates of energy metabolism in CSF. , 1995, The American journal of psychiatry.

[46]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[47]  Manzar Ashtari,et al.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine , 1995, The Lancet.

[48]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[49]  Francine M. Benes,et al.  The effects of haloperidol on synaptic patterns in the rat striatum , 1985, Brain Research.